The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating neuropsychiatric diseases and disorders.

In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells. A significant anti-metastatic effect has been observed on a metastatic nude-mouse model of human pancreatic cancer BxPC-3 cell lines constructed orthotopically as a result of therapeutic treatment with the lipofullerene-saccharide conjugate.

Materials and methods for forming self-assembled peptoid structures that are extremely stable, crystalline, free-standing and self-repairing are described. Based on the peptoid design, peptoid membranes in a 2D arrangement was able toroll into single-walled nanotubes with tunable sizes, diameters, thicknesses and stiffnesses as well as tailorable functions result. Crystalline nanomaterials made through this facile solution crystallization and anisotropic formation process are highly tailorable and exhibit a number of properties advantageous for applications such as water decontamination, cellular adhesion, imaging, surface coating, biosensing, energy conversion, biocatalysis or other applications.

The invention relates generally to the field of nanoparticles, and more specifically, in one embodiment, to bio-nanoparticle elements formed from materials comprised of self-assembling protein molecules, which are capable of coating one or more type of elements. In another invention embodiment, the invention relates to a protein that coats one or more elements in order to modify or improve one or more characteristic of the element, including, but not limited to, stability, rigidity, or functionality of the element that is coated with the instant invention.

The disclosure discloses a glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and a preparation method thereof, and belongs to the field of biomedicine. The disclosure loads a chemotherapeutic drug onto specific metal-organic frameworks, and modifies targeted molecule galactose on the surface of the materials through amide reaction. The biocompatibility and cytotoxicity of the obtained hepatic targeted therapeutic drug have been carefully evaluated at the cellular level. The hepatic targeted therapeutic drug of the disclosure has good stability and acidic pH triggered drug release property, and can exert the synergistic therapeutic effect of photodynamic therapy and chemotherapy. In addition, in vivo behavioral tracing and therapeutic efficacy are evaluated in mouse models with subcutaneous solid tumor and tumor in situ, and the disclosure is expected to play a huge role in clinical applications.

The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents.

A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules. In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 microns or less. The composition may be homogeneous.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

Composites comprising a metal carbonate and organic agent included within a crystal lattice of the metal carbonate are disclosed. Process of preparing the composites is also disclosed. Uses of the composites, in medicine, are also disclosed.